Harmful and costly delays in the diagnosis and care of patients with Alzheimer’s disease and dementia led the Alzheimer’s Association to create new guidelines designed to bring consistency to diagnosis and treatment. The new research framework is the most compelling piece, says geriatrician Saket Saxena, MD.
Our third annual report on the state of Alzheimer’s drug development shows shifts toward prevention studies and disease-modifying therapies against a backdrop of sluggish development speed.
In the wake of two lifetime achievement awards, Dr. Jeffrey Cummings reflects on how the field has changed over 30 years, future hopes and challenges, and his advice for young clinician-scientists.
A new effort to screen patients for cognitive impairment during primary care visits will help identify those who need geriatric or other specialized care earlier, which may help improve long-term outcomes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Wine experts have enhanced structural and functional measures in brain areas linked to their expertise, a new study shows. A researcher discusses potential implications for neural plasticity in adults.
A new paper from a group of Alzheimer’s experts outlines what’s needed to meet the federal government’s goal of effective prevention or treatment by 2025. Lead author Jeffrey Cummings, MD, ScD, gives the lowdown.
An expert panel at Cleveland Clinic’s recent Medical Innovation Summit explained why much earlier intervention will be key to success in AD therapeutics — and how biomarkers and big data will help us get there.